β³ Fetching live dividend data...
Home βΊ Calculator βΊ BLRX Dividend Calculator 2026
BioLineRx Ltd. Β· NASDAQ
Price: $3.12 Β· Annual div: $2.00/share Β· Frequency: quarterly Β· Payout ratio: 50% Β· Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in BLRX β $1.42M in 10 years Β· $46,103.35/month
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. Β· Privacy Policy
Ready to invest? Open BLRX position with:
Real after-tax yield depends on where you live and how you hold BLRX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| πΊπΈ Roth IRA / 401k | 0% | 64.10% | 61.30% | $6,410 / yr |
| πΊπΈ US Taxable (15%) β | 15% | 54.48% | 51.68% | $5,448 / yr |
| πΊπΈ US Taxable (20%) | 20% | 51.28% | 48.48% | $5,128 / yr |
| π¬π§ UK ISA | 0% | 64.10% | 61.30% | $6,410 / yr |
| π¬π§ UK Taxable | 8.75% | 58.49% | 55.69% | $5,849 / yr |
| π¨π¦ TFSA | 0% | 64.10% | 61.30% | $6,410 / yr |
| π¨π¦ CA Taxable | 25% | 48.07% | 45.27% | $4,808 / yr |
| π¦πΊ Super (pension) | 15% | 54.48% | 51.68% | $5,448 / yr |
| π¦πΊ AU Taxable | 30% | 44.87% | 42.07% | $4,487 / yr |
| π©πͺ DE Taxable | 26.375% | 47.19% | 44.39% | $4,719 / yr |
| π«π· FR Taxable | 30% | 44.87% | 42.07% | $4,487 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
BLRX pays quarterly β 4 times per year. Next ex-div: TBD.
How BLRX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for BLRX sourced from FMP /financial-growth endpoint β real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Other | 2016-10-05 | 49,800 | $0.84 | $41.7K | ||
| Other | 2017-10-05 | 19,800 | $0.92 | $18.2K | ||
| Other | 2018-10-05 | 19,800 | $0.89 | $17.7K | ||
| Other | 2019-10-02 | 199,800 | $0.36 | $71.1K | ||
| Other | 2020-10-02 | 79,800 | $0.37 | $29.4K | ||
| Other | 2021-10-02 | 79,800 | $0.39 | $31.0K | ||
| Other | 2024-10-03 | 360,000 | $0.09 | $30.6K | ||
| Other | 2023-10-03 | 360,000 | $0.08 | $29.2K | ||
| Other | 2025-01-01 | 2,055,000 | $0.05 | $106.9K | ||
| Other | 2016-10-05 | 49,800 | $0.84 | $41.7K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores β lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the BLRX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β
BioLineRx Ltd. (BLRX) is currently trading at $3.12, 98% below its 52-week high. The current dividend yield is 64.10% based on an annual payout of $2.00 per share.
BioLineRx Ltd. (BLRX) is a healthcare stock currently trading at $3.12 with a dividend yield of 64.10%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only β not financial advice.
News aggregated from public sources via Finnhub & RSS. For informational purposes only.
Real users. No sign-up required to leave a review.
βFinally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.β
βI've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly β $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.β
βReally solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.β
βAs someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.β
βThe Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.β
Reviews reflect users' personal experiences. Not financial advice.
Leave a review β